Float Short %

28.2

Margin Of Safety %

Put/Call OI Ratio

0.75

EPS Next Q Diff

0.1

EPS Last/This Y

0.53

EPS This/Next Y

1.36

Price

14.01

Target Price

31.67

Analyst Recom

Performance Q

7.03

Relative Volume

1.71

Beta

-0.12

Ticker: KALV

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	KALV	12.88	0.74	0.34	18395
2025-08-18	KALV	13.35	0.75	0.45	13576
2025-08-19	KALV	12.82	0.73	0.00	14373
2025-08-20	KALV	12.91	0.71	0.00	14685
2025-08-21	KALV	12.96	0.71	0.00	14638
2025-08-22	KALV	13.44	0.71	2.21	14637
2025-08-25	KALV	13	0.72	0.34	14792
2025-08-26	KALV	13.18	0.72	0.35	14877
2025-08-27	KALV	13.61	0.72	0.03	14906
2025-08-28	KALV	13.52	0.72	0.99	14902
2025-08-29	KALV	13.47	0.82	0.87	24927
2025-09-02	KALV	14.3	0.82	0.05	24966
2025-09-03	KALV	14.15	0.82	0.03	25004
2025-09-04	KALV	15.2	0.82	0.47	25078
2025-09-05	KALV	15.84	0.81	4.28	25350
2025-09-08	KALV	15.88	0.84	0.05	25788
2025-09-09	KALV	15.59	0.84	0.36	25827
2025-09-10	KALV	15.36	0.83	0.08	25948
2025-09-11	KALV	14.78	0.76	0.09	27641
2025-09-12	KALV	14.03	0.75	0.55	27796
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	KALV	12.89	-10.2	-	-3.31
2025-08-18	KALV	13.35	-10.2	-	-3.31
2025-08-19	KALV	12.81	-10.2	-	-3.31
2025-08-20	KALV	12.93	-10.2	-	-3.31
2025-08-21	KALV	12.95	-10.2	-	-3.31
2025-08-22	KALV	13.43	-10.2	-	-3.31
2025-08-25	KALV	13.00	-10.2	-	-3.31
2025-08-26	KALV	13.16	-10.2	-	-3.31
2025-08-28	KALV	13.51	-10.2	-	-3.31
2025-08-29	KALV	13.48	-10.2	-	-3.31
2025-09-02	KALV	14.30	-10.2	-	-3.31
2025-09-03	KALV	14.15	-10.2	-	-3.31
2025-09-04	KALV	15.18	-10.2	-	-3.31
2025-09-05	KALV	15.82	-10.2	-	-3.16
2025-09-08	KALV	15.96	-9.8	-	-3.16
2025-09-09	KALV	15.58	-9.8	-	-3.16
2025-09-10	KALV	15.40	-9.8	-	-3.16
2025-09-11	KALV	14.81	-9.8	-	-3.16
2025-09-12	KALV	14.01	-9.8	-	-3.16
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	KALV	-0.83	-6.20	26.06
2025-08-18	KALV	-0.83	-7.59	25.95
2025-08-19	KALV	-0.93	-7.59	26.95
2025-08-20	KALV	-0.74	-7.59	26.95
2025-08-21	KALV	-0.74	-7.59	26.95
2025-08-22	KALV	-0.74	-7.59	26.95
2025-08-25	KALV	-0.74	-1.46	25.26
2025-08-26	KALV	-1.06	-1.46	25.26
2025-08-27	KALV	-1.11	-1.46	25.21
2025-08-28	KALV	-1.11	-1.46	25.21
2025-08-29	KALV	-0.89	-1.46	26.94
2025-09-02	KALV	-0.89	-1.46	26.79
2025-09-03	KALV	-0.91	-1.46	26.79
2025-09-04	KALV	-0.91	-1.46	26.79
2025-09-05	KALV	-0.91	-1.46	26.79
2025-09-08	KALV	-0.91	-1.45	26.79
2025-09-09	KALV	-0.91	-1.45	26.79
2025-09-10	KALV	-0.96	-1.45	26.79
2025-09-11	KALV	-0.91	-1.45	28.20
2025-09-12	KALV	-0.91	-1.45	28.20
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.99

Avg. EPS Est. Current Quarter

-0.83

Avg. EPS Est. Next Quarter

-0.89

Insider Transactions

-0.91

Institutional Transactions

-1.45

Beta

-0.12

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

68.9

Max Drawdown 5-Year %

-90.1

Target Price

31.67

P/E

Forward P/E

15.4

PEG

P/S

489.4

P/B

17.29

P/Free Cash Flow

EPS

-4

Average EPS Est. Cur. Y

-3.16

EPS Next Y. (Est.)

-1.8

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-14242.57

Relative Volume

1.71

Return on Equity vs Sector %

-217.2

Return on Equity vs Industry %

-204

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.15

EBIT Estimation

KalVista Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 270

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

stock quote shares KALV – KalVista Pharmaceuticals Inc Stock Price stock today

news today KALV – KalVista Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch KALV – KalVista Pharmaceuticals Inc yahoo finance google finance

stock history KALV – KalVista Pharmaceuticals Inc invest stock market

stock prices KALV premarket after hours

ticker KALV fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: KALV

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y